Search results
Found 22107 matches for
Established in March 2020, the RECOVERY trial tests a range of potential treatments for COVID-19, including azithromycin, a widely used antibiotic that also reduces inflammation. The azithromycin arm of the trial was established to determine whether or not the drug has a meaningful benefit among patients hospitalised with COVID-19. A preliminary analysis shows no significant difference in the primary endpoint of 28-day mortality; there was also no evidence of beneficial effects on the risk of progression to mechanical ventilation or length of hospital stay.
Peter Horby
FRS Peter Horby - Moh Family Foundation Professor of Emerging Infections and Global Health
Brian Angus
BSc, MBChB, DTM&H, FRCP, MD, FFTM Brian Angus - Professor of Practice, Medical Education and Reader in Infectious Diseases
